FOXO4-DRI is an experimental synthetic peptide designed to make some senescent cells undergo programmed cell death. Senescent cells have stopped dividing after damage or other stress; some remain active and release signals that influence nearby tissue. Mouse studies have reported improvements in selected kidney, testicular and lung-injury measurements. Other experiments found that removing these cells failed to improve cartilage formation or harmed the lung circulation. No completed human treatment study of FOXO4-DRI was identified in this review.
Overview
The name refers to a manufactured peptide derived from a p53-binding region of FOXO4, a protein that regulates gene activity. The peptide has a cell-entry component and uses D-amino acids in a reversed sequence arrangement, called D-retro-inverso or DRI. Baar and colleagues specified a 46-amino-acid D-form peptide with a reported molecular weight of 5,358.2, approximately 5.36 kilodaltons of peptide mass. Endogenous FOXO4 and administered FOXO4-DRI are different materials. Baar et al. (2017)
Molecular profile
- Form
- Synthetic cell-penetrating D-retro-inverso peptide derived from a p53-binding region of FOXO4 Source
- Molecule type
- Peptide; distinct from endogenous FOXO4 protein Source
- Reported length
- 46 amino acids in the original D-form construct Source
- Reported molecular weight
- Approximately 5.36 kDa for the original peptide (reported MW 5,358.2); the paper does not specify a commercial salt Source
Forms and derivatives
Endogenous FOXO4
Gene-regulating protein whose interaction with p53 motivated the peptide. Measuring or changing that protein is a different intervention from administering FOXO4-DRI.
Corresponding L-form peptide
The L-form comparator did not reproduce the senescent-cell killing observed with FOXO4-DRI in the original experiment.
Other FOXO4–p53-interfering peptides
Different engineered peptides require their own identity and evidence. A common target does not establish identical selectivity or exposure.
The distinction matters biologically. In the original cell experiments, the corresponding L-form peptide did not reproduce the loss of senescent-cell viability. Findings about FOXO4 gene expression, other FOXO proteins or other peptides aimed at the same interaction do not establish the effects of FOXO4-DRI.
Uses and research areas
Researchers have tested FOXO4-DRI in damaged or aged tissues, asking whether reducing senescent cells improves a particular organ measurement. These include kidney blood markers in aged mice, testosterone production in aged male mice, scar-forming cells in injured mouse lungs, and human cartilage or scar tissue kept outside the body. These settings examine different cell populations and outcomes. Baar et al. (2017), Zhang et al. (2020), Han et al. (2022), Huang et al. (2021), Kong et al. (2025)
Pulmonary fibrosis means scar tissue builds up in the lungs. Pulmonary hypertension means abnormally high pressure in the lung blood vessels. Favorable fibrosis findings do not establish a benefit in pulmonary hypertension: Born and colleagues reported an adverse response in a different mouse vascular model. Born et al. (2023)
Mechanism of action
Some senescent cells resist the usual machinery for programmed cell death, or apoptosis. FOXO4 can bind the stress-response protein p53 and help maintain this state. In Baar and colleagues’ experiments, FOXO4-DRI competed for p53 binding, p53 moved out of the cell nucleus, and enzymes that execute apoptosis became active. This explained preferential killing in the tested cell systems; it did not establish that every senescent cell in every organ is expendable. Baar et al. (2017)
Bourgeois and colleagues clarified the physical interaction in 2025 using structural measurements of purified proteins. The peptide bound a flexible part of p53 called transactivation domain 2, or TAD2. Both its FOXO4-derived region and its cell-entry component contributed to binding. The study strengthens the molecular explanation while leaving organ selectivity, exposure and human outcomes to separate experiments. Bourgeois et al. (2025)
Pharmacokinetics
The selected studies do not establish a human blood half-life, absorption, clearance or distribution volume for FOXO4-DRI. The original investigators detected peptide-associated staining inside cultured cells for at least 72 hours. That is an intracellular detection result after laboratory exposure; it does not measure how fast intact peptide disappears from blood after administration. Baar et al. (2017)
The D-retro-inverso chemistry is a feature of molecular identity. It does not supply a numerical blood half-life. Neither the spacing of animal treatments nor the later persistence of an organ response can fill that missing measurement.
Research findings
Kidney measurements improved in two mouse aging settings
Baar and colleagues studied mice with a DNA-repair disorder that causes rapid aging-like changes, alongside mice allowed to age naturally. Compared with phosphate-buffered saline controls, treated mice showed lower kidney senescence-associated measurements and lower blood urea; naturally aged mice also had lower creatinine. These blood waste products inform kidney filtering function. The rapid-aging mice ran more on wheels, but wheel activity varied too much in the naturally aged animals for a meaningful activity experiment. This was not a lifespan trial. Baar et al. (2017)
Testosterone rose in aged mice, with a missing cellular link
Zhang and colleagues compared FOXO4-DRI with phosphate-buffered saline in 20–24-month-old male mice, with six animals in each aged group. Serum testosterone was higher in treated mice 30 days after the intervention, while body and testis weights did not show a clear difference. Human testicular specimens in the same paper supplied observations about FOXO4 location; the men were not treated. The authors acknowledged that they had not directly demonstrated removal of senescent Leydig cells inside the aged mice. Leydig cells are the testicular cells that make testosterone. Zhang et al. (2020)
Cell clearance did not improve cartilage formation
Huang and colleagues expanded human cartilage cells through repeated divisions, then compared peptide-treated cells with untreated cells. More than half of the extensively expanded cells were removed, and senescence-associated measurements fell. Yet the remaining cells did not form cartilage better in the subsequent pellet-culture test. Lower expression of some secreted inflammatory factors did not establish better tissue production. Huang et al. (2021)
Fibrotic lung injury and keloid tissue supplied different follow-ups
Han and colleagues found less collagen deposition and fewer senescence-associated cells in bleomycin-injured mouse lungs after FOXO4-DRI than after the injury alone. The report carries a 2024 correction: representative cell-analysis images in Figure 6B had been placed in the wrong treatment panel. The authors state that the conclusion is unchanged. Han et al. (2022), Han et al. (2024), correction
In 2025, Kong and colleagues tested fibroblasts and pieces of human keloid scar tissue outside the body. Fibroblasts made senescent by restricted culture conditions showed more apoptosis after treatment, with p53 shifting out of nuclei. Normal-skin fibroblasts made senescent under the same conditions also died more often. The experiment did not measure scar recurrence or healing in treated patients. Kong et al. (2025)
Safety and tolerability
The strongest caution comes from the pulmonary circulation. Born and colleagues reported loss of endothelial cells, the cells lining vessels, and adverse changes in lung circulation in serotonin-transporter-overexpressing mice given FOXO4-DRI or the separate senolytic ABT263. The abstract does not give the direction or size of a pressure change specifically for the peptide. Other experiments in the paper used genetic cell removal or ABT263 and found higher pulmonary pressures and heart enlargement. The endothelial-cell loss in the peptide comparison is itself a meaningful adverse observation. Born et al. (2023)
The original aging study did not observe a noticeable fall in platelets, the blood cells needed for clotting, at its tested follow-up. This limited finding cannot establish chronic toxicity, immune safety, cancer risk or tolerability in people. FOXO4-DRI remains experimental; no FDA-approved FOXO4-DRI treatment or completed clinical safety study was identified for this review. Baar et al. (2017)
What the research means
FOXO4-DRI helped test whether some senescent cells actively contribute to tissue dysfunction. The answer depends on the organ and model. Kidney blood markers improved in aged mice, cartilage-forming ability failed to improve after cell clearance, and the pulmonary-vessel study identified harm. A useful future treatment would need to reach the intended cells, spare necessary ones and demonstrate a meaningful clinical outcome. The present studies do not establish a general reversal of aging or longer human life.
FAQs
Is FOXO4-DRI the FOXO4 protein made by the body?
FOXO4-DRI is a synthetic peptide designed around part of FOXO4 and joined to a component that helps it enter cells. Endogenous FOXO4 is a larger protein that regulates gene activity. The D-retro-inverso chemistry is part of the experimental peptide’s identity. Baar et al. (2017)
Has FOXO4-DRI been shown to extend lifespan?
The original mouse paper measured tissue function and selected signs of frailty; it did not establish an increase in lifespan. The selected reports do not demonstrate longer human life. Baar et al. (2017)
Does eliminating senescent cells always improve the tissue?
In expanded human cartilage cells, clearance did not improve later cartilage formation. In a mouse pulmonary-vessel model, treatment was associated with worse lung circulation and endothelial-cell loss. These findings make the cell type and organ consequential. Huang et al. (2021), Born et al. (2023)
Did the testosterone study treat older men?
Human testicular samples were examined for FOXO4, but the treatment experiment involved aged male mice. Serum testosterone rose in the mice, and direct removal of senescent Leydig cells in those animals was not demonstrated. Zhang et al. (2020)
What is the blood half-life of FOXO4-DRI?
The selected reports do not provide a validated human blood half-life. Detection inside cultured cells for at least 72 hours does not measure elimination from blood. Baar et al. (2017)
Why is the 2024 lung-paper correction relevant?
Han and colleagues corrected duplicated representative cell-analysis panels in Figure 6B. The authors state that their conclusion is unchanged. Han et al. (2024), correction
Comparisons and related reading
References
Introduces the D-retro-inverso peptide and tests senescent cells, chemotherapy injury and two mouse aging settings. Kidney blood markers improved; naturally aged mice had too much running-wheel variation for a meaningful activity comparison.
Separates human testicular observations from experiments on mouse cells and aged male mice. Testosterone rose in treated mice; direct elimination of senescent Leydig cells inside those animals was not established.
Human cartilage cells grown extensively in culture lost senescent cells after treatment, but their ability to form cartilage did not improve. Cell clearance and tissue repair therefore need separate measurements.
In mice with bleomycin lung injury, treatment reduced collagen buildup and senescence-associated measurements. A 2024 correction replaces misplaced flow-cytometry panels in Figure 6B.
Corrects duplicated representative cell-analysis images in Figure 6B. The authors state that their overall conclusion is unchanged.
Provides an adverse counterexample: mice overexpressing the serotonin transporter developed disturbed lung circulation and lost pulmonary endothelial cells after FOXO4-DRI or ABT263. Other arms used genetic clearance or ABT263 and cannot supply peptide-specific numerical estimates.
Tests human scar fibroblasts and tissue outside the body. Both keloid and normal-skin fibroblasts made senescent by culture conditions showed more cell death; no patients received the peptide.
Structural experiments locate direct peptide binding on a flexible p53 region. Both the FOXO4-derived part and the cell-entry component contact p53, refining the explanation of the original peptide.
Glossary
- Senescence
- A state in which a cell stops dividing after stress or damage and can continue to influence nearby tissue.
- Senolytic
- An intervention intended to eliminate senescent cells.
- Apoptosis
- An organized process of cell death carried out by the cell’s own machinery.
- D-retro-inverso
- A peptide design using D-amino acids and reversed residue order relative to the corresponding L-form segment.
- Endothelial cell
- A cell that lines the inside of a blood vessel.
- Leydig cell
- A cell in the testis that produces testosterone.